172 related articles for article (PubMed ID: 19678810)
1. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema.
Querques G; Bux AV; Martinelli D; Iaculli C; Noci ND
Acta Ophthalmol; 2009 Sep; 87(6):623-30. PubMed ID: 19678810
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of intravitreal triamcinolone acetonide in long standing diabetic macular edema: a microperimetry and optical coherence tomography study.
Grenga P; Lupo S; Domanico D; Vingolo EM
Retina; 2008 Oct; 28(9):1270-5. PubMed ID: 18664938
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study.
Rinaldi M; Chiosi F; dell'Omo R; Romano MR; Parmeggiani F; Semeraro F; Mastropasqua R; Costagliola C
Br J Clin Pharmacol; 2012 Dec; 74(6):940-6. PubMed ID: 22486651
[TBL] [Abstract][Full Text] [Related]
4. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy.
Mikhail M; Stewart S; Seow F; Hogg R; Lois N
Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.
Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL
Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286
[TBL] [Abstract][Full Text] [Related]
7. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.
Wroblewski JJ; Wells JA; Gonzales CR
Am J Ophthalmol; 2010 Jan; 149(1):147-54. PubMed ID: 19875087
[TBL] [Abstract][Full Text] [Related]
8. Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months.
Arevalo JF; Sanchez JG; Wu L; Maia M; Alezzandrini AA; Brito M; Bonafonte S; Lujan S; Diaz-Llopis M; Restrepo N; Rodríguez FJ; Udaondo-Mirete P;
Ophthalmology; 2009 Aug; 116(8):1488-97, 1497.e1. PubMed ID: 19545900
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with variability in response of diabetic macular oedema after intravitreal triamcinolone.
Mohamed S; Leung GM; Chan CK; Lai TY; Lee VY; Liu DT; Li KK; Li PS; Lam DS
Clin Exp Ophthalmol; 2009 Aug; 37(6):602-8. PubMed ID: 19702711
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab for diabetic macular oedema: 5-year results of the Pan-American Collaborative Retina Study group.
Arevalo JF; Lasave AF; Wu L; Acon D; Farah ME; Gallego-Pinazo R; Alezzandrini AA; Fortuna V; Quiroz-Mercado H; Salcedo-Villanueva G; Maia M; Serrano M; Rojas S;
Br J Ophthalmol; 2016 Dec; 100(12):1605-1610. PubMed ID: 26912377
[TBL] [Abstract][Full Text] [Related]
12. Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema.
Soliman W; Vinten M; Sander B; Soliman KA; Yehya S; Rahman MS; Larsen M
Acta Ophthalmol; 2008 Jun; 86(4):365-71. PubMed ID: 18028237
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
Fang X; Sakaguchi H; Gomi F; Oshima Y; Sawa M; Tsujikawa M; Ikuno Y; Kamei M; Kusaka S; Tano Y
Acta Ophthalmol; 2008 Nov; 86(7):800-5. PubMed ID: 18547274
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema.
Cervera E; Diaz-Llopis M; Udaondo P; Garcia-Delpech S
Eye (Lond); 2008 Sep; 22(9):1180-2. PubMed ID: 18425062
[TBL] [Abstract][Full Text] [Related]
15. Short-term fluctuation of diabetic macular edema after intravitreal ranibizumab injection.
Querques G; Bux AV; Martinelli D; Iaculli C; Del Curatolo MV; Delle Noci N
Retina; 2009 Oct; 29(9):1274-81. PubMed ID: 19696699
[TBL] [Abstract][Full Text] [Related]
16. Phacoemulsification with intravitreal bevacizumab and triamcinolone acetonide injection in diabetic patients with clinically significant macular edema and cataract.
Akinci A; Muftuoglu O; Altınsoy A; Ozkılıc E
Retina; 2011 Apr; 31(4):755-8. PubMed ID: 21124251
[TBL] [Abstract][Full Text] [Related]
17. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.
Sultan MB; Zhou D; Loftus J; Dombi T; Ice KS;
Ophthalmology; 2011 Jun; 118(6):1107-18. PubMed ID: 21529957
[TBL] [Abstract][Full Text] [Related]
18. Phacoemulsification with intravitreal bevacizumab injection in diabetic patients with macular edema and cataract.
Akinci A; Batman C; Ozkilic E; Altinsoy A
Retina; 2009; 29(10):1432-5. PubMed ID: 19898181
[TBL] [Abstract][Full Text] [Related]
19. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Cunningham ET; Adamis AP; Altaweel M; Aiello LP; Bressler NM; D'Amico DJ; Goldbaum M; Guyer DR; Katz B; Patel M; Schwartz SD;
Ophthalmology; 2005 Oct; 112(10):1747-57. PubMed ID: 16154196
[TBL] [Abstract][Full Text] [Related]
20. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
